Alcon Inc. (ALC) announced on Monday that it has agreed with LENSAR, Inc. (LNSR) to terminate their previously announced merger agreement.
The medical device company Alcon cited prolonged regulatory review and related costs as the reason for the decision, after opposition from the Federal Trade Commission.
The regulatory review had been ongoing for nearly a year. Alcon, which operates in the ophthalmology industry, stated that it remains focused on advancing cataract surgery technologies to improve efficiency for surgeons and outcomes for patients.
ALC closed Monday's trading at $77.79 up $0.47 or 0.61 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.